‘Hopeful milestone’: Health Canada approves 2nd drug to slow Alzheimer’s

This is the second disease-slowing drug for Alzheimer’s that has been approved in Canada, after Health Canada approved lecanemab, commercially known as Leqembi, in October 2025.